Peptide Comparison
Defensin (HBD-3)vsThymalin
Most potent human beta-defensin (45 amino acids) with unique salt-insensitive antimicrobial activity — kills MRSA at MIC 0.5-1.0 μg/mL regardless of salt concentration, disrupts biofilms at 4-8 μg/mL, and retains full bactericidal function even without its disulfide bonds — representing a next-generation antimicrobial peptide template for combating antibiotic resistance
Russian thymic peptide complex that rejuvenates immune function and supports healthy aging
At a Glance
Quick
comparison
Dose Range
Defensin (HBD-3)
1–50 μg/mL (research)
Thymalin
5–10 mg
Frequency
Defensin (HBD-3)
As needed
Thymalin
Once daily
Administration
Defensin (HBD-3)
Topical application (research/wound care)
Thymalin
Intramuscular injection
Cycle Length
Defensin (HBD-3)
Ongoing/indefinite
Thymalin
4-6 weeks
Onset Speed
Defensin (HBD-3)
Rapid (hours to days)
Thymalin
Moderate (1-2 weeks)
Evidence Level
Defensin (HBD-3)
Moderate human trials (Phase 1-2)
Thymalin
Limited human trials
Efficacy
Benefit
ratings
Fighting Drug-Resistant Bacteria
Wound Healing
Immune System Support
Immune Restoration
Longevity Support
Disease Prevention
Technical Data
Compound
specifications
Defensin (HBD-3)
Molecular Formula
Approximately C220H340N64O62S6 (45-amino acid peptide with 3 disulfide bonds)
Molecular Weight
~5,155 Da (mature peptide)
Half-Life
Short systemic half-life (minutes) typical of cationic peptides; disulfide-bonded form provides protease resistance at local tissue sites; linear form shows adequate stability for topical applications
Bioavailability
Topical application achieves high local concentrations; maintains activity in physiological salt environments (unique); linear form retains activity enabling simplified formulation; not intended for oral or systemic delivery
CAS Number
Not assigned (endogenous human peptide; research-grade available from peptide suppliers)
Thymalin
Molecular Formula
Complex mixture; active dipeptide EW: C16H19N3O5
Molecular Weight
Polypeptide complex; components 250-1000 Da; active dipeptide EW ~321 Da
Half-Life
Not precisely characterized for complex; immune effects persist weeks post-administration
Bioavailability
High via intramuscular or subcutaneous injection
CAS Number
63958-90-7
Protocols
Dosing
tiers
Defensin (HBD-3)
Thymalin
Applications
Best
suited for
Defensin (HBD-3)
Research into anti-MRSA therapeutics and alternatives to vancomycin for resistant infections
Defensin (HBD-3) is particularly well-suited for individuals focused on research into anti-mrsa therapeutics and alternatives to vancomycin for resistant infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Development of antimicrobial wound dressings and medical device coatings
Defensin (HBD-3) is particularly well-suited for individuals focused on development of antimicrobial wound dressings and medical device coatings. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-biofilm strategies for chronic wound infections and implant-associated infections
Defensin (HBD-3) is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and implant-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Applications requiring antimicrobial activity in physiological or high-salt environments
Defensin (HBD-3) is particularly well-suited for individuals focused on applications requiring antimicrobial activity in physiological or high-salt environments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymalin
Aging Adults Seeking Immune Support
Thymalin is especially valuable for people over 55 whose thymus gland has naturally shrunk with age. By stimulating thymic function, it helps restore the immune training center that your body relies on to fight infections and stay healthy.
Longevity and Anti-Aging Protocols
Clinical studies tracking patients for 6-8 years showed Thymalin reduced mortality by 2.0-2.1-fold. Combined with Epitalon, the mortality reduction reached an impressive 4.1-fold, making this combination one of the most studied longevity peptide protocols.
Seasonal Illness Prevention
Research shows Thymalin cuts respiratory infection rates by 2.0-2.4-fold. A short 10-day course before cold and flu season can significantly boost your immune defenses for months afterward.
Safety Profile
Side
effects
Defensin (HBD-3)
Common
- Local site irritation
- Transient inflammatory response
- Mild wound bed changes
Uncommon
- Localized allergic reaction
- Mild cytotoxicity at high concentrations
Serious
- No serious adverse effects documented at therapeutic concentrations
Thymalin
Common
- No side effects in most patients
- Mild injection site reaction
Uncommon
- Transient low-grade fever
- Mild flu-like symptoms
- Temporary headache
Serious
- Severe allergic reaction
Research Status
Safety
& evidence
Defensin (HBD-3)
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Defensin HBD-3 is not FDA-approved and has no completed human clinical trials, existing only in research contexts with in vitro and animal study data. Animal toxicology studies demonstrate no major systemic toxicity at doses exceeding therapeutic levels, but human immunological responses to exogenously administered defensin peptides have not been characterized. Risks include potential immune activation, cross-reactivity with self-antigens (due to HBD-3 expression in healthy epithelial cells), development of anti-peptide antibodies, and possible tolerance development with repeated dosing. Bacterial and fungal resistance to defensin-based therapy is theoretically possible. No human pharmacokinetics, dose-ranging studies, Phase 1 safety assessments, or clinical efficacy data exist.
Contraindications
- xKnown hypersensitivity to defensin peptides or formulation components
- xPregnancy and breastfeeding — insufficient safety data for exogenous defensin administration
- xActive autoimmune conditions — potential for immune activation through monocyte/macrophage recruitment
- xSevere hepatic or renal impairment — peptide clearance may be altered for any systemic exposure
Thymalin
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Thymalin has an excellent safety profile based on over 40 years of clinical use in Russia. Most patients experience zero side effects, and the peptide complex has been described as 'practically non-toxic' in research literature. It has been used safely in thousands of patients, including elderly populations over extended periods.
Contraindications
- xActive thymic tumors or malignancies
- xKnown hypersensitivity to animal-derived peptide products
- xPregnancy and breastfeeding (insufficient safety data)
- xSevere uncontrolled autoimmune disease without medical supervision
Decision Guide
Which is
right for you?
Choose Defensin (HBD-3) if...
- Research into anti-MRSA therapeutics and alternatives to vancomycin for resistant infections
- Development of antimicrobial wound dressings and medical device coatings
- Anti-biofilm strategies for chronic wound infections and implant-associated infections
- Applications requiring antimicrobial activity in physiological or high-salt environments
Choose Thymalin if...
- Immune system restoration in aging adults
- Longevity and healthy aging support
- Reducing infection frequency and severity
- Multi-system health optimization